Yup.
I work for “medium pharma”. We spend between 1 and 5 dollars per experiment (depending on the cell type). We run close to 2 MILLION experiments every week. We are still years away from any of those experiments yielding a safe compound that can move on to human trials, assuming we don’t run out of money first.
Targeting drugs for rare diseases won’t be profitable until we achieve proper high-throughput experimentation, analysis, and somehow streamline the FDA approval process. The government needs to fund academic research on these diseases, but no university lab can match the kind of experiment production that we’re already doing in industry.
I used to think there was no such thing as a stupid question. You have now changed my mind.